Literature DB >> 8339218

Immunohistochemical expression of embryonal marker TRA-1-60 in carcinoma in situ and germ cell tumors of the testis.

A Giwercman1, P W Andrews, N Jørgensen, J Müller, N Graem, N E Skakkebaek.   

Abstract

BACKGROUND: Testicular cancer is preceded by the noninvasive stage of carcinoma in situ (CIS). According to a recent hypothesis, testicular CIA cells are germ cells transformed in fetal life. The idea of an embryonal origin of testicular germ cell neoplasia would be strengthened by the finding of antigenic similarity between fetal germ cells, CIS cells, and invasive testicular germ cell tumors.
METHODS: Monoclonal antibody (MoAb) TRA-1-60 raised against a human embryonal carcinoma cell line was immunohistochemically tested on 21 fetal gonads (11 male gonads and 10 female gonads; 11th-24th week of gestation). In addition, TRA-1-60 was tested on tissue from 27 testes with CIS, 11 testes with invasive testicular cancer, and 24 adult and 4 infant testicular control specimens.
RESULTS: Expression of TRA-1-60 was found in germ cells of six female and two male fetal gonads. In addition, 26 of 27 adult human testes with CIS, 7 of 8 seminomas, and 3 of 3 embryonal carcinomas were TRA-1-60 positive.
CONCLUSIONS: The study demonstrated an antigenic link between fetal germ cells, cells of CIS and seminomas, and embryonal carcinomas. The results provided additional evidence for the hypothesis that testicular neoplasia arises during early fetal life and CIS cells are malignant fetal gonocytes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8339218     DOI: 10.1002/1097-0142(19930815)72:4<1308::aid-cncr2820720426>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

Review 1.  [Testicular intraepithelial neoplasms (TIN). An indication for radiotherapy?].

Authors:  J Classen; K P Dieckmann; V Loy; M Bamberg
Journal:  Strahlenther Onkol       Date:  1998-04       Impact factor: 3.621

Review 2.  Common stemness regulators of embryonic and cancer stem cells.

Authors:  Christiana Hadjimichael; Konstantina Chanoumidou; Natalia Papadopoulou; Panagiota Arampatzi; Joseph Papamatheakis; Androniki Kretsovali
Journal:  World J Stem Cells       Date:  2015-10-26       Impact factor: 5.326

3.  Stemness-Related Markers in Cancer.

Authors:  Wenxiu Zhao; Yvonne Li; Xun Zhang
Journal:  Cancer Transl Med       Date:  2017-06-08

4.  Recurrent seminomas: clinical features and biologic implications.

Authors:  Avik Som; Rui Zhu; Charles C Guo; Eleni Efstathiou; Li Xiao; Louis L Pisters; Angabin Matin; Shi-Ming Tu
Journal:  Urol Oncol       Date:  2010-09-06       Impact factor: 3.498

5.  Expression of the glycolipid globotriaosylceramide (Gb3) in testicular carcinoma in situ.

Authors:  J L Kang; E Rajpert-De Meyts; J Wiels; N E Skakkebaek
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

6.  Intratubular germ cell neoplasms of the testis and bilateral testicular tumors: clinical significance and management options.

Authors:  Michael C Risk; Timothy A Masterson
Journal:  Indian J Urol       Date:  2010 Jan-Mar

7.  Glycan stem-cell markers are specifically expressed by spermatogonia in the adult non-human primate testis.

Authors:  T Müller; K Eildermann; R Dhir; S Schlatt; R Behr
Journal:  Hum Reprod       Date:  2008-07-10       Impact factor: 6.918

8.  TRA-1-60+, SSEA-4+, POU5F1+, SOX2+, NANOG+ Clones of Pluripotent Stem Cells in the Embryonal Carcinomas of the Testes.

Authors:  Marek Malecki; Xenia Tombokan; Mark Anderson; Raf Malecki; Michael Beauchaine
Journal:  J Stem Cell Res Ther       Date:  2013-04-02

9.  Heterogeneity of expression of immunohistochemical tumour markers in testicular carcinoma in situ: pathogenetic relevance.

Authors:  E Rajpert-De Meyts; M Kvist; N E Skakkebaek
Journal:  Virchows Arch       Date:  1996-06       Impact factor: 4.064

Review 10.  Current concepts of radiation treatment of carcinoma in situ of the testis.

Authors:  A Giwercman; H von der Maase; M Rørth; N E Skakkebaek
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.